Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation

Clinical and Experimental Immunology

Volumn 140, Issue 1, 2005, Pages 126-137

  Desombere, Isabelle ^a   Cao, T ^a   Gijbels, Y ^a   Leroux Roels, G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antigen presentation; DRB1*0301; HBsAg; Hepatitis B vaccines; Non response

Indexed keywords

CD14 ANTIGEN; CD86 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; HAPLOTYPE; HEPATITIS B; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; INCIDENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD80; ANTIGENS, CD86; CELL LINE; COCULTURE TECHNIQUES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HLA-DP ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES;

EID: 16244387925     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02749.x     Document Type: Article

References (52)

1. Craven DE, Awdeh ZL, Kunches LM et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986; 105:356-60.
2. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336:196-204.
3. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982; 307:1481-6.
4. Walker M, Szmuness W, Stevens CE, Rubinstein P. Genetics of anti-HBs responsiveness. I. HLA-DR7 and nonresponsiveness to hepatitis vaccination. Transfusion 1981; 21:601.
5. Milich DR, Leroux-Roels GG. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003; 2:248-57.
6. Usonis V, Kuhnl P, Brede HD, Doerr HW. Humoral immune response after hepatitis-B-vaccination: kinetics of anti-HBs antibodies and demonstration of HLA antigens. Zentralbl Bakteriol Mikrobiol Hyg [A] 1986; 262:377-84.
7. Varla-Leftherioti M, Papanicolaou M, Spyropoulou M et al. HLA-associated non-responsiveness to hepatitis B vaccine. Tissue Antigens 1990; 35:60-3.
8. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. Jama 1988; 260:1734-8.
9. Dondi E, Finco O, Mantovani V, Mele L, Ruberto G, Cuccia M. Involvement of HLA and C4 in the nonresponsiveness to hepatitis B vaccine. Fund Clin Immunol 1996; 4:73.
10. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998; 51:593-604.
11. McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 1997; 50:8-14.
12. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004; 39:978-88.
13. Hohler T, Stradmann-Bellinghausen B, Starke R et al. C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 2002; 37;387-92.
14. Martinetti M, De Silvestri A, Belloni C et al. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin Immunol 2000; 97:234-40.
15. De Silvestri A, Pasi A, Martinetti M et al. Family study of nonresponsiveness to hepatitis B vaccine confirms the importance of HLA class III C4A locus. Genes Immun 2001; 2:367-72.
16. Celis E, Karr RW. Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule. J Virol 1989; 63:747-52.
17. + suppressor T cells. Hum Immunol 1988; 22:9-17.
18. Lango-Warensjo A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 1998; 52:374-80.
19. Alper CA, Kruskall MS, Marcus-Bagley D et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321:708-12.
20. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J Exp Med 1992; 175:495-502.
21. Egea E, Iglesias A, Sakzar M et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991; 173:531-8.
22. Leroux-Roels G, Van Hecke E, Michielsen W, Voet P, Hauser P, Petre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994; 12:812-18.
23. Hohler T, Meyer CU, Notghi A et al. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol 1998; 59:212-18.
24. Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G. Non-responders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 1995; 154:520-9.
25. Desombere I, Gijbels Y, Verwulgen A, Leroux-Roels G. Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines. Clin Exp Immunol 2000; 122:390-9.
26. Salazar M, Deulofeut H, Granja C et al. Norma HBsAg presentation and T-cell defect in the immune response of nonresponders. Immunogenetics 1995; 41:366-74.
27. + T cells. J Immunol 2000; 164:265-72.
28. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol 1998; 18:389-418.
29. Leroux-Roels G, Desombere I, Cobbaut L et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines. Vaccine 1997; 15:1732-6.
30. Andre FE, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Med J 1987; 63 (Suppl. 2):169-77.
31. Cabezon T, Rutgers T, Biemans Q, Vanderbrugge D, Voet P, De Wilde M. A new hepatitis B vaccine containing preS1 and preS2 epitopes from S. cerevisiae. New York: Cold Spring Harbor Laboratory Press, 1990:199.
32. Leroux-Roels G, Desombere I, De Tollenaere G et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults. Vaccine 1997; 15:1724-31.
33. Hollinger BL, Adam E, Heiberg D, Melnick LJ. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter H, Maynard J, eds. Viral Hepatitis: 1981 International Symposium. Philadelphia: Franklin Institute Press, 1982;451.
34. Ono Y, Onda H, Sasada R, Igarashi K, Sugino Y, Nishioka K. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucl Acids Res 1983; 11:1747-57.
35. Buyse I, Decorte R, Baens M et al. Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization. Tissue Antigens 1993; 41:1-14.
36. Marsh SG, Albert ED, Bodmer WF et al. Nomenclature for factors of the HLA system, 2002. Tissue Antigens 2002; 60:407-64.
37. Falkoff RM, Peters M, Fauci AS. T cell enrichment and depletion of human peripheral blood mononuclear cell preparations. Unexpected findings in the study of the functional activities of the separated populations. J Immunol Meth 1982; 50:39-49.
38. Dozmorov I, Eisenbraun MD, Lefkovits I. Limiting dilution analysis: from frequencies to cellular interactions. Immunol Today 2000; 21:15-8.
39. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355:561-5.
40. Grob PJ, Jilg W, Milne A, Townsend TR. Unresolved issues in hepatitis B immunization. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore, MD: Williams & Wilkins, 1990:856.
41. Van Damme P, Banatvala JE. Vaccine induced protection against hepatitis B. BMJ 2003; 326:105.
42. Shouval, D. Hepatitis B vaccines. J Hepatol 2003; 39 (Suppl. 1): S70-6.
43. Caillat-Zucman S, Gimenez JJ, Wambergue F et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998; 53:1626-30.
44. Olikowsky T, Wang ZQ, Dudhane A, Horowitz H, Conti B, Hoffmann MK. Two distinct pathways of human macrophage differentiation are mediated by interferon-gamma and interleukin-10. Immunology 1997; 91:104-8.
45. Zissel G, Ernst M, Schlaak M, Muller-Quernheim J. Pharmacological modulation of the IFNgamma-induced accessory function of alveolar macrophages and peripheral blood monocytes. Inflamm Res 1999; 48:662-8.
46. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 1991; 137:429-37.
47. Yi-qun Z, Joost van Neerven RJ, Kasran A, de Boer M, Ceuppens JL. Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens. Int Immunol 1996; 8:37-44.
48. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106:255-8.
49. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-58.
50. Milich DR. Influence of C4A deficiency on nonresponse to HBsAg vaccination: a new immune response gene. J Hepatol 2002; 37:396-9.
51. Fischer MB, Ma M, Goerg S et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996; 157:549-56.
52. Hohler T, Reuss E, Evers N et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002; 360:991-5.